These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10218762)

  • 1. Clinical and laboratory manifestations of anti-factor V antibodies.
    Ortel TL
    J Lab Clin Med; 1999 Apr; 133(4):326-34. PubMed ID: 10218762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations.
    Ortel TL; Moore KD; Quinn-Allen MA; Okamura T; Sinclair AJ; Lazarchick J; Govindan R; Carmagnol F; Kane WH
    Blood; 1998 Jun; 91(11):4188-96. PubMed ID: 9596666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological consequences of topical bovine thrombin.
    Zehnder JL; Leung LL
    Am J Pathol; 2001 Dec; 159(6):2371. PubMed ID: 11733385
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of antibodies to human thrombin and factor V in a pediatric patient exposed to topical bovine thrombin.
    Lo CY; Jones C; Glader B; Zehnder JL
    Pediatr Blood Cancer; 2010 Dec; 55(6):1195-7. PubMed ID: 20979176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function.
    Chouhan VD; De La Cadena RA; Nagaswami C; Weisel JW; Kajani M; Rao AK
    Thromb Haemost; 1997 Feb; 77(2):343-9. PubMed ID: 9157594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin.
    Rapaport SI; Zivelin A; Minow RA; Hunter CS; Donnelly K
    Am J Clin Pathol; 1992 Jan; 97(1):84-91. PubMed ID: 1728869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin.
    Zehnder JL; Leung LL
    Blood; 1990 Nov; 76(10):2011-6. PubMed ID: 2242423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids.
    Takeya H; Mori T; Gabazza EC; Kuroda K; Deguchi H; Matsuura E; Ichikawa K; Koike T; Suzuki K
    J Clin Invest; 1997 May; 99(9):2260-8. PubMed ID: 9151800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms that regulate the anticoagulant function of coagulation factor V.
    Thorelli E
    Scand J Clin Lab Invest Suppl; 1999; 229():19-26. PubMed ID: 10097286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of cephradine-induced acquired factor V inhibitors: a case report.
    Wu MT; Pei SN
    Ann Pharmacother; 2010 Oct; 44(10):1673-6. PubMed ID: 20807866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coagulopathy as a result of factor V inhibitor after exposure to bovine topical thrombin.
    Neschis DG; Heyman MR; Cheanvechai V; Benjamin ME; Flinn WR
    J Vasc Surg; 2002 Feb; 35(2):400-2. PubMed ID: 11854743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation.
    Favaloro EJ; Posen J; Ramakrishna R; Soltani S; McRae S; Just S; Aboud M; Low J; Gemmell R; Kershaw G; Coleman R; Dean M
    Blood Coagul Fibrinolysis; 2004 Oct; 15(8):637-47. PubMed ID: 15613918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-beta2-glycoprotein I autoantibodies, in vitro thrombin generation, and the antiphospholipid syndrome.
    Hanly JG; Smith SA
    J Rheumatol; 2000 Sep; 27(9):2152-9. PubMed ID: 10990227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired thrombin and FV inhibitors upon aortic bioprosthetic valve replacement.
    Hervent AS; Schepens M; Bourgeois M; Emmerechts J
    Haemophilia; 2014 Jul; 20(4):e354-6. PubMed ID: 24948407
    [No Abstract]   [Full Text] [Related]  

  • 15. Severe bleeding due to factor V inhibitor after repeated operations using fibrin sealant containing bovine thrombin.
    Muntean W; Zenz W; Edlinger G; Beitzke A
    Thromb Haemost; 1997 Jun; 77(6):1223. PubMed ID: 9241765
    [No Abstract]   [Full Text] [Related]  

  • 16. Factor V Inhibitors: A Diagnostic and Therapeutic Challenge.
    Olson NJ; Ornstein DL
    Arch Pathol Lab Med; 2017 Dec; 141(12):1728-1731. PubMed ID: 29189062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coagulation factor V.
    Duga S; Asselta R; Tenchini ML
    Int J Biochem Cell Biol; 2004 Aug; 36(8):1393-9. PubMed ID: 15147718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acquired factor V inhibitors in a polytraumatized patient].
    Tukić L; Stamatović D; Tarabar O; Elez M; Zorić M; Mandić-Radić S
    Vojnosanit Pregl; 2005; 62(7-8):587-90. PubMed ID: 16171024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired factor V deficiency in a patient with a urinary tract infection presenting with haematuria followed by multiple haemorrhages with an extremely low level of factor V inhibitor: a case report and review of the literature.
    Wang X; Qin X; Yu Y; Wang R; Liu X; Ji M; Zhou M; Chen C
    Blood Coagul Fibrinolysis; 2017 Jun; 28(4):334-341. PubMed ID: 27428013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acquired factor V deficiency: a rare bleeding disorder with variable clinical presentations].
    Alcantara M; Ducastelle S; Rugeri L; Dargaud Y
    Rev Med Interne; 2011 May; 32(5):e59-61. PubMed ID: 20638758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.